Summer Sale
50% off Premium Yearly
NASDAQ:IBRX
ImmunityBio (IBRX)
Financials 
Technical Analysis 
Jun 11, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
ImmunityBio, Inc. is making significant strides in the field of immunotherapy, focusing on innovative therapies aimed at combating cancers and infectious diseases. In its recent quarter, the company reported a loss of -0.07 USD per share, which was better than the estimated -0.11 USD loss, showcasing a strong performance against expectations. Additionally, revenues surpassed estimates, reaching 32.06 million USD compared to an expected 31.88 million USD. analysts are projecting a slight improvement in earnings with an expected loss of -0.09 USD per share and revenues of 37.88 million USD for the next quarter. Notably, social media buzz has surged, with an increase of 1250% and 31%, reflecting growing interest and awareness around the company's activities and potential.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA. Social media mentions are up 31% in the past 24h.
- «
- ‹
- 1
- ›
- »
ImmunityBio (IBRX) Frequently Asked Questions
What is ImmunityBio stock symbol?
ImmunityBio is a American stock, trading under the symbol IBRX (previously IBRX-Q on Stockchase) on the NASDAQ (IBRX). It is usually referred to as NASDAQ:IBRX or IBRX
Is ImmunityBio a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on IBRX (previously IBRX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for ImmunityBio.
Is ImmunityBio a good investment or a top pick?
ImmunityBio was recommended as a Top Pick by The Weekly Buzzing Stocks by Billy Kawasaki on 2026-01-22. Read the latest stock experts ratings for ImmunityBio.
Why is ImmunityBio stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ImmunityBio.
Is ImmunityBio worth watching?
ImmunityBio is covered by Stockchase experts and is worth watching.
What is ImmunityBio stock price?
On 2026-06-12, ImmunityBio (IBRX) stock closed at a price of $7.10.
In the last quarter, the company reported -0.07 USD per share, beating the -0.11 USD estimate by 34.66%. Revenue for the same period reached 32.06 M USD, despite the estimate of 31.88 M USD. For the next quarter, analysts expect -0.09 USD in earnings per share and 37.88 M USD in revenue. Social media mentions are up 1250% in the past 24h.